SIBO Explained: Causes, Breath Tests, and What Actually Treats It

Small intestinal bacterial overgrowth (SIBO) is what happens when bacteria that normally live in the colon multiply in the small intestine, where they don’t belong, and start fermenting your food before you can absorb it. The result is bloating, gas, abdominal pain, and altered stools that overlap heavily with IBS — so much that pooled data show roughly 38% of people diagnosed with IBS also test positive for SIBO on breath testing (Chen et al. 2018, PubMed). Diagnosis is done with a hydrogen-methane breath test, treatment usually starts with the antibiotic rifaximin or a 2-week elemental diet, and recurrence is the rule, not the exception.

Key takeaways

• SIBO is excess bacteria in the small intestine, where bacterial counts should be low. Fermentation in the wrong location produces the bloating, gas, and bowel changes.
• A hydrogen-methane breath test is the standard diagnostic. A rise in hydrogen of ≥20 ppm by 90 minutes is positive; methane ≥10 ppm at any point flips the diagnosis to intestinal methanogen overgrowth (IMO), which is more constipation-linked (Pimentel et al., North American Consensus).
• Rifaximin is the most-studied antibiotic. A 14-day course resolves symptoms in roughly 50% of patients (2020 ACG Guideline).
• Recurrence is common. One large series reported 13% relapse at 3 months, 28% at 6 months, and 44% at 9 months after a successful course (Lauritano et al., reviewed in Springer 2024).
• Long-term PPI use is a documented risk factor: pooled SIBO prevalence among PPI-treated patients was ~37% vs ~20% in controls (systematic review, J Clin Med 2025).

What SIBO actually is

Most of your bacteria live in the colon. The small intestine is supposed to be a relatively bacteria-light zone — gastric acid, bile, fast motility, and the ileocecal valve all act to keep it that way. SIBO is the failure of those defenses: bacterial counts climb past the normal threshold (usually defined as ≥10³ CFU/mL on small-bowel aspirate), and the small intestine starts behaving like a second colon (Mayo Clinic).

Two things go wrong when that happens:

1. Bacteria ferment carbs before you absorb them, producing hydrogen, methane, and hydrogen sulfide. That’s where the bloating, distention, and post-meal gas come from.
2. Bacterial enzymes deconjugate bile acids and damage the brush border, which can cause fat and B12 malabsorption in more advanced cases.

The symptom profile is non-specific, which is why SIBO gets missed and why it gets over-diagnosed in equal measure.

Symptoms: what SIBO feels like

The clinical picture overlaps almost completely with IBS, which is part of why the two get tangled. Common features:

• Bloating and visible abdominal distention that worsens through the day
• Excess gas and belching
• Diarrhea (more common with hydrogen-predominant SIBO)
• Constipation (more common with methane-predominant IMO)
• Abdominal pain or cramping after meals
• A sensation of fullness with small meals
• In more severe cases: weight loss, fatigue, iron or B12 deficiency, steatorrhea (fatty, hard-to-flush stools)

If your symptoms match this list, the next step isn’t self-treatment with herbal antimicrobials — it’s a breath test ordered through a clinician.

Who gets SIBO: the real risk factors

SIBO is rarely random. Almost every case has a structural, motility, or medication-related explanation behind it:

• Slow small-bowel motility. Diabetes (especially with gastroparesis), scleroderma, hypothyroidism, and post-viral motility damage all slow the migrating motor complex, the cleaning wave that normally sweeps bacteria out of the small intestine between meals.
• Anatomical changes. Prior abdominal surgery (gastric bypass, bowel resection, adhesions), small-bowel diverticula, or an incompetent ileocecal valve create stagnant pockets where bacteria accumulate.
• Low stomach acid. Long-term proton pump inhibitor (PPI) use is the most-cited drug exposure. A 2025 systematic review and meta-analysis found pooled SIBO prevalence of ~37% in PPI-treated patients vs ~20% in controls, with each additional month of PPI therapy adding ~4 percentage points to the risk (Tsoukas et al., J Clin Med 2025).
• Inflammatory bowel disease. Crohn’s strictures and surgical changes raise SIBO risk substantially.
• Older age. Slower motility, more medications, and more prior surgeries stack the risk.

Identifying the underlying driver matters because if you treat the bacteria without addressing the cause, you’re setting up the relapse cycle.

How SIBO is diagnosed: the breath test

The gold standard in theory is small-bowel aspirate culture, but it’s invasive (requires endoscopy), prone to contamination, and rarely done in practice. The clinical standard is a hydrogen-methane breath test.

How the test works

You drink a measured dose of a sugar — usually 75 g of glucose or 10 g of lactulose — and breathe into a collection device every 15 to 30 minutes for 2 to 3 hours (North American Consensus, Pimentel et al.). Bacteria that ferment the sugar produce hydrogen and/or methane, which are absorbed across the gut wall, carried to the lungs, and exhaled. A breath analyzer measures the gases in parts per million (ppm).

Two main results matter:

• Hydrogen rise ≥20 ppm above baseline within 90 minutes is positive for SIBO.
• Methane ≥10 ppm at any time point is positive for intestinal methanogen overgrowth (IMO) — driven mainly by archaea (Methanobrevibacter smithii), not true bacteria, and more closely tied to constipation.

Glucose vs lactulose

Glucose is absorbed in the proximal small intestine, so a rise in breath hydrogen on a glucose test points specifically to proximal overgrowth. Lactulose is non-absorbable and travels the full length of the small bowel, so it can pick up more distal overgrowth but is more prone to false positives from fast transit. The 2020 ACG Clinical Guideline endorses either glucose-hydrogen or lactulose-hydrogen breath testing in symptomatic patients, particularly those with prior abdominal surgery or IBS-pattern symptoms.

Test limitations

Breath testing is imperfect. False positives happen with rapid orocecal transit (the sugar reaches the colon faster than 90 minutes). False negatives happen when hydrogen-only testing misses methane-producing or hydrogen-sulfide-producing overgrowth. That’s why methane is now measured alongside hydrogen as a standard.

How SIBO is treated

Treatment has three jobs: knock down the overgrowth, support recovery, and address the underlying cause so it doesn’t come back. Most protocols start with one of two approaches.

Rifaximin

Rifaximin is a non-absorbable antibiotic that stays in the gut lumen, which is part of why it’s tolerated well. The standard SIBO course is 550 mg three times daily for 14 days.

What the evidence shows:

• A 14-day course resolves symptoms in roughly 50% of patients with hydrogen-predominant SIBO, summarized in the 2020 ACG Guideline.
• Methane-positive overgrowth (IMO) responds less well to rifaximin alone. Guidelines and recent reviews suggest adding neomycin (or, in some protocols, metronidazole) to target the methanogens.
• Repeat courses are common. Patients often go through two or three rounds before finding durable symptom relief.

Elemental diet

An elemental diet is a 2 to 3 week period of nothing but pre-digested liquid nutrition (free amino acids, simple sugars, fats). The goal is to feed you without feeding the bacteria, which lack the substrate they need to ferment.

The original Cedars-Sinai work from Pimentel’s group reported eradication in about 80% of patients after a 14-day elemental diet, and a more recent open-label trial of a palatable elemental formula reported cure rates of 100% in SIBO-only patients and 75% in combined SIBO/IMO (Rezaie et al., Gastroenterology 2025). It works, but compliance is brutal — two weeks of nothing but formula is hard, and palatability has historically been the main barrier.

Addressing the underlying cause

Whichever route you take, the bacteria will return if motility, anatomy, or medication exposure aren’t addressed. Practical levers:

• Reassess PPI use with your prescribing clinician. Long-term PPIs are sometimes essential and sometimes a deprescribing opportunity.
• Optimize diabetes control if gastroparesis or autonomic neuropathy is in play.
• Prokinetics (low-dose erythromycin, prucalopride, or motilin agonists) are sometimes used between treatments to keep the migrating motor complex active.
• Eat with longer gaps (avoiding constant snacking) lets the cleansing motor complex run between meals.

SIBO and IBS: the overlap that matters

The IBS-SIBO question keeps coming up in clinic for one reason: a meta-analysis of 25 studies found SIBO prevalence of 38% in IBS patients vs ~10% in healthy controls (Chen et al. 2018). SIBO is more common in IBS-D (~35%) than IBS-C (~22%) (epidemiology review, PMC 2023).

That doesn’t mean every IBS case is “really” SIBO. It means a meaningful fraction of patients labeled IBS — especially those with bloating, post-meal distention, and a clear food-trigger pattern — have a treatable overgrowth that gets missed when the workup stops at “you have IBS.” The low-FODMAP diet works partly because it starves the same bacteria that would feed an overgrowth, which is why some clinicians use it as a complementary tool after rifaximin.

If you’ve been diagnosed with IBS but have classic SIBO features — bloating that builds through the day, gas peaks within an hour of meals, response to past antibiotic courses — a breath test is a reasonable conversation with your gastroenterologist.

FAQ

Is SIBO the same as a leaky gut? No. SIBO is excess bacteria in the wrong location of the small intestine. “Leaky gut” refers to increased intestinal permeability — a separate concept that may or may not be associated, depending on the case. They can coexist, but the diagnosis and treatment are different.

How long does rifaximin take to work? Most patients who respond notice improvement during the 14-day course, with bloating and stool consistency normalizing in the 2 to 4 weeks after finishing. If symptoms haven’t improved 4 weeks post-treatment, the overgrowth either didn’t clear or the underlying cause is driving rapid recurrence.

Do over-the-counter herbal antimicrobials work for SIBO? A 2014 Johns Hopkins comparative study found a herbal combination (oregano, berberine, wormwood) was comparable to rifaximin for clearing breath-test-positive SIBO, but the evidence base is thinner than for prescription antibiotics. Talk to a clinician before self-treating — antimicrobials, herbal or not, aren’t risk-free.

Can probiotics treat SIBO? Mixed evidence. Some studies show benefit, especially with specific strains; others find no effect or worsening symptoms. Until trials clarify which strains help which subtype, probiotics aren’t a first-line SIBO treatment.

Will the low-FODMAP diet cure SIBO? The low-FODMAP diet reduces symptoms by starving the fermenting bacteria, but it doesn’t eradicate the overgrowth. Most clinicians use it adjunctively, not as monotherapy. Long-term restriction also reshapes the microbiome in ways that may not be helpful, so it’s a tool, not a destination.

How often does SIBO come back? Often. One frequently cited series reported relapse in ~13% at 3 months, ~28% at 6 months, and ~44% at 9 months after successful treatment (Springer 2024 review). Recurrence is why addressing the underlying driver — motility, PPI, anatomy — matters as much as the antibiotic.

The bottom line

SIBO is real, common in patients labeled “IBS,” and treatable — but the diagnosis is only half the work. A breath test confirms the overgrowth, rifaximin or an elemental diet knocks it down in roughly half to four-fifths of cases, and the underlying motility or medication driver determines whether you stay better or relapse within months. If you’ve been bloated and gassy for years without an answer, SIBO is worth asking about by name at your next GI visit.

Tracking what your stool looks like before, during, and after a SIBO course gives your clinician something concrete to work with. PoopCheck logs Bristol type, color, and consistency from a photo, so you can see exactly when a rifaximin course shifted you from Type 6 back toward Type 4 — and catch the relapse the moment it starts, instead of three months in. See our diarrhea guide for the differential when stools are loose, and our floating stool explainer for what fat malabsorption looks like.

Sources

1. Small intestinal bacterial overgrowth — symptoms and causes — Mayo Clinic.
2. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth — Pimentel M et al., Am J Gastroenterol 2020.
3. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus — Rezaie A et al., Am J Gastroenterol 2017.
4. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis — Chen B et al., J Gastroenterol 2018.
5. Epidemiology of small intestinal bacterial overgrowth — Efremova I et al., World J Gastroenterol 2023.
6. Small Intestinal Bacterial Overgrowth (review of diagnosis and management) — Current Infectious Disease Reports 2024.
7. The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis — J Clin Med 2025.
8. Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients With Intestinal Microbial Overgrowth — Rezaie A et al., Gastroenterology 2025.